Category: GeoVax Recent News

Awarded BARDA Project NextGen (PNG) contract to advance GeoVax’s multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study   BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent   Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;…

Atlanta, GA, September 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events: H.C. Wainwright 26th Annual Global Investment Conference Speaker: David Dodd, Chairman & CEO Date/Time: September 9, 2024…

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor   Atlanta, GA, July 31, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced the next steps for the clinical development of its Gedeptin® cancer therapy, following…

GeoVax to Host Conference Call at 4:30 PM ET   Atlanta, GA, July 30, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets.…

Company to discuss recent BARDA Project NextGen award for its next-generation COVID-19 vaccine and provide progress update across its clinical development pipeline   ATLANTA, GA, July 16, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, is pleased to announce that it has been invited to…

Atlanta, GA, July 11, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,085,000 shares of the Company’s common stock (or common…

Award of BARDA Project NextGen contract represents a significant milestone event; total value of award to GeoVax and its CRO partner total approximately $367-388 million   BARDA-funded 10,000-participant Phase 2b study will evaluate and compare GeoVax’s multi-antigen vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19   Progress across pipeline with planned data readouts in…

10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19   Study is Funded by BARDA through Project NextGen, executed through its Clinical Studies Network   Atlanta, GA, June 27, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious…

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin®   ATLANTA, GA, May 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the BIO International Convention 2024 being held…

10,000-participant randomized Phase 2b study will evaluate and compare GeoVax’s multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA’s Clinical Studies Network   Project NextGen is a $5 billion initiative by the U.S. Department of Health and Human Services to develop innovative vaccines and therapeutics providing broader and more durable protection against…

Atlanta, GA, May 17, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 802,844 shares of the Company’s common stock (or common…

Presented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven mechanisms that contribute to the broad efficacy of the vaccine candidate  Significant milestone achieved towards implementation of a commercially validated manufacturing system  Progress across pipeline with planned data readouts for GEO-CM04S1 in multiple trials and Gedeptin® in healthy patient boost trial on…